What does 'peptide therapy' actually refer to?

It umbrellas a wide range, from clinical peptide drugs (injectable, oral, topical) to topical peptides in cosmetics. Medically it points to prescription/research peptides like BPC-157, GHK-Cu, melanotan, and AOD-9604, while in search trends it includes topical cosmetics (Matrixyl, GHK-Cu) and supplements (collagen peptides).

Does rising searches mean rising clinical evidence?

These are separate streams. Search shows consumer attention spread; efficacy is verified by clinical data. Within the peptide category, evidence depth varies wildly. GHK-Cu and Matrixyl topicals have 20-50 years of accumulated data, but compounds like BPC-157 are still mostly animal-stage with limited human trials. Search trends should be cross-referenced with evidence-tier per ingredient.

Why are NAD and GLP-1 co-searched with peptides?

All three reach the same higher-order desire: slowing or reversing aging. Peptides are the topical/body-recovery tool, NAD addresses cellular energy and DNA repair, GLP-1 reframes weight and metabolism. The pattern reflects consumers stacking categories rather than picking a single drug or supplement.

Peptide Therapy Searches Up 281% on Google, Hitting the 2026 Search Trend Peak

What consumers care about shows up most honestly in search trends. As of April 2026, “peptide therapy” reached a search trend peak. Up 281% YoY on Google, 459% on TikTok, 412% on Instagram. The real signal is not the spike of a single keyword, but the simultaneous spike of co-search terms.

Co-search trend movement

Co-search terms that surged alongside peptides in the same window:

NAD: up 601%
GLP-1: up 177%
Anti-aging: up 162%

All three categories tap the same higher-order desire to slow or reverse aging. Peptides are tools for topical and body recovery; NAD addresses cellular energy and DNA repair; GLP-1 restructures weight and metabolism. Consumers are stacking categories rather than picking a single tool, and search behavior reveals the pattern.

What drove this

Three factors converged.

First, the GLP-1 era’s side effects. Wegovy, Ozempic, and Mounjaro users facing facial fat loss, muscle loss, and skin laxity have generated new aesthetic demand. Peptides plug into that demand cleanly.

Second, longevity and biohacker community mainstreaming. Influence from David Sinclair, Peter Attia, and similar figures has spread to general consumers, pulling NAD boosters, NMN, peptides, and metformin into mainstream search vocabulary.

Third, K-beauty’s peptide familiarity. For Korean consumers, peptides have long been a standard topical ingredient. In the U.S. and Europe, marketing positioned them as a new category, fueling search growth.

Market data follows

Search trends are converting to market data quickly.

P&G’s Ouai Haircare launched a $50 topical hair peptide “Bond Repair Balm” in March 2026
Neurogan Health reported 32.8% wrinkle depth reduction in a 12-week trial of 2% GHK-Cu body care
Symrise unveiled Cellexora MD plant-derived exosomes at in-cosmetics Global April 2026
BASF launched NeoHelix Regenerate (CHP-based precision peptide) + SkinNexus Collag3n at the same event

From raw material companies to finished-product brands, simultaneous launches happened within a single quarter, and the market is rapidly aligning under the “peptide therapy” umbrella.

Search doesn’t prove efficacy

The biggest risk in this trend is conflating search interest with efficacy data. Within the peptide category, evidence depth varies dramatically.

Thick evidence: GHK-Cu (50+ years clinical), Matrixyl (20+ years), hydrolyzed collagen peptides (20+ years), Signaline (15+ years)
Limited evidence: BPC-157 (mostly animal), TB-500 (mostly animal), melanotan (accumulated side effect reports), AOD-9604 (limited human trials)

Search volume moves independently of evidence depth, and marketing campaigns can drive searches. Consumers should check evidence depth before search popularity. The FDA’s restriction recommendation on BPC-157 (2023) is an example of regulation following the gap.

What co-search means

The simultaneous surge in NAD, GLP-1, and anti-aging matters at the market level too. Categories are bundling into “stacks” rather than standing alone. The shift is from single-product sales to packaged offerings combining “weight loss + muscle preservation + topical anti-aging + cellular energy.”

Some U.S. clinics already bundle GLP-1 prescription with NAD IV + peptide topicals + collagen supplements, with package pricing at $500-1,500 per month. Korean clinics rolling out Wegovy prescriptions are forming similar bundles in early stages.

What to verify

Before chasing search trends, check.

What outcome you want: topical anti-aging, weight loss, cellular recovery, muscle preservation; the peptide type differs by goal.
Evidence depth: start with peptides backed by thick clinical data.
Pricing: even at the same efficacy concentration, form (topical/oral/injectable) varies pricing 5-50x.
Prescription vs over-the-counter: some peptides like BPC-157 carry legal risk for non-prescription use in Korea and the U.S.

What’s next

Categories that show 281% search growth typically reach a 12-18 month inflection point of either market settlement or hype collapse. Peptides will likely split: thick-evidence categories (GHK-Cu, Matrixyl, collagen) will settle into mainstream anti-aging stacks, while thin-evidence categories (BPC-157, TB-500) face regulatory and consumer trust pressure. H2 2026 is poised to be the inflection point.

Source: Glossy / Google Trends 2026